Aaron Friedman

In this session, learn how Merck is modernizing its drug discovery process with the integration of biological foundation models. Merck shares firsthand experience into how the company has modernized its generative biology inference stack using AWS HealthOmics, which helps them scale and unlock new insights.

The human genome acts as the biological blueprint of the human body and has the potential to transform how we discover new therapies and treat disease. But researchers face a common set of challenges processing omics data in the cloud, from scaling compute across millions of samples to analyzing trends.

Like any industry, Life Sciences organizations are adopting machine learning to advance capabilities across their value chain, such as in clinical trials, adverse event prediction, and real-world evidence. Success of these initiatives is predicated on the quality of data that informs models.